TJ011

TJ011 is an investigational small molecule therapeutic being developed by Tuojie Biotech (拓界生物医药) for the treatment of solid tumors. It is part of the company's oncology pipeline, which focuses on the discovery and development of innovative small molecule and small nucleic acid drugs. As of early 2024, TJ011 is in the early stages of development, and while it is categorized as a tumor-targeting agent, its specific molecular target has not been publicly disclosed in detail. The drug represents part of Tuojie Biotech's efforts to expand its portfolio of antineoplastic therapies alongside other candidates like TJ012 and TJ013.